Tenax Therapeutics (TENX) AI Stock Analysis

• Market Cap: $25.25M
• Dividend Yield: N/A
• Average Volume (3M): 37.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: N/A
• EPS Growth: 84.17%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -5.31
• Shares Outstanding: 3,970,385
• 10 Day Avg. Volume: 27,722
• 30 Day Avg. Volume: 37,946
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $25.00
• Price Target Upside: 296.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Tenax Therapeutics is heavily reliant on equity financing for liquidity with no revenue generation, leading to operational losses and an unattractive valuation. Technical indicators provide a neutral outlook, but significant risks persist without a clear path to profitability.

Positive Factors

Clinical Trials

TENX recently reported extraordinary patient adherence in the ongoing Ph3 LEVEL trial with over 95% of randomized patients remaining on therapy.

Financial Performance

As of December 31, 2024, Tenax reported cash and cash equivalents of $94.9M, and in March 2025, the company raised an additional $25M in gross proceeds through a private placement.

Market Potential

Key asset TNX-103 has multi-billion dollar sales potential with forecasted sales of $2.2B, highlighting significant market opportunity.

Negative Factors

Clinical Trial Risks

In the downside scenario in which the Ph3 trial fails, TENX shares could potentially gap down to the low single digits.

Operating Expenses

TENX reported 4Q24 total operating expenses of $7.3M, above the estimate of $4.7M, driven by higher R&D spending.

Regulatory Challenges

TENX will have to conduct a second Ph3 trial in order to meet FDA’s request for subject drug exposure.

Tenax Therapeutics Business Overview & Revenue Model

Company Description

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing pharmaceutical products for the critical care market. The company primarily operates in the biotechnology and pharmaceutical sectors, with its core product offerings centered around novel therapeutic solutions for pulmonary hypertension and other cardiovascular diseases. Tenax Therapeutics is committed to advancing clinical programs and leveraging its expertise to bring innovative treatments to market that address unmet medical needs.

How the Company Makes Money

Tenax Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is centered on the successful advancement of its drug candidates through clinical trials, regulatory approvals, and eventual market entry. Revenue streams include potential product sales, licensing agreements, and partnerships with other pharmaceutical companies. Key factors contributing to its earnings include the successful demonstration of clinical efficacy and safety of its drug candidates, strategic alliances with industry partners, and potential collaborations for the distribution and marketing of its products. The company's focus on targeting niche markets with high unmet medical needs may also play a significant role in its revenue generation strategies.

Tenax Therapeutics Financial Statement Overview

Summary

Tenax Therapeutics exhibits strong liquidity and equity due to external financing but lacks revenue generation and suffers from continuous operational losses. Financial stability is heavily reliant on equity financing, posing potential risks if this trend continues without revenue improvements.

Income Statement

The company has consistently reported zero revenue over the years, leading to negative gross profit and net income figures. There is no visible revenue growth trajectory, and profitability metrics such as EBIT and EBITDA are negative, indicating significant losses.

Balance Sheet

The company has a strong equity position with zero total debt and a high equity ratio. However, the lack of revenue and consistent net losses are concerning for long-term sustainability. The cash reserves have been bolstered, which improves liquidity but does not offset the operational losses.

Cash Flow

Operating and free cash flows are negative, reflecting ongoing cash burn. While financing activities have significantly increased cash reserves, this reliance on external financing is not sustainable without revenue generation. The cash flow situation poses a risk if the company cannot turn operations profitable.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
5.79K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
120.00	0.00	-7.57K	-113.33K	-108.98K	-114.75K
	EBIT
1.40M	0.00	―	-11.05M	-32.73M	-9.87M
	EBITDA
-14.53M	0.00	-8.23M	-10.93M	-32.36M	-9.74M
	Net Income Common Stockholders
-6.96M	-17.60M	-7.71M	-11.04M	-32.73M	-9.87M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
837.17K	94.85M	9.79M	2.12M	5.58M	6.71M
	Total Assets
3.09M	96.69M	11.68M	3.40M	5.99M	6.87M
	Total Debt
7.20K	0.00	500.90K	807.89K	290.78K	305.04K
	Net Debt
-829.97K	-94.85M	-9.29M	-1.32M	-5.29M	-5.95M
	Total Liabilities
1.47M	4.69M	3.59M	1.91M	1.75M	2.24M
	Stockholders Equity
1.63M	91.99M	8.10M	1.49M	4.24M	4.63M
Cash Flow		Free Cash Flow
-12.46M	-14.81M	-5.90M	-12.02M	-10.86M	-9.28M
	Operating Cash Flow
-12.46M	-14.81M	-5.90M	-12.01M	-10.86M	-9.27M
	Investing Cash Flow
-1.24K	0.00	2.84K	-2.32K	452.61K	20.11K
	Financing Cash Flow
99.63M	99.87M	13.57M	8.55M	―	10.60M

Tenax Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.30
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TENX, the sentiment is Neutral. The current price of 6.3 is above the 20-day moving average (MA) of 6.29, below the 50-day MA of 6.42, and above the 200-day MA of 4.85, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.58 is Neutral, neither overbought nor oversold. The STOCH value of 61.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TENX.

Tenax Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GDTC	54 Neutral	$25.39M	―	-26.36%	―	―	29.75%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
OVID	44 Neutral	$22.01M	―	-33.88%	―	44.50%	49.72%
VYNE	44 Neutral	$23.27M	―	-56.54%	―	18.16%	86.65%
CGTX	35 Underperform	$24.30M	―	-157.19%	―	―	-0.38%
TENX	30 Underperform	$25.25M	―	-35.17%	―	―	84.17%
PYPD	30 Underperform	$28.02M	―	-1038.73%	―	―	-85.67%

Tenax Therapeutics Corporate Events

Tenax Therapeutics Appoints Interim CFO Thomas McGauley

Tenax Therapeutics, Inc. has appointed Thomas A. McGauley as Interim Chief Financial Officer, effective December 2, 2024. With over 25 years of experience in finance and executive roles, McGauley will lead the company’s financial operations under a consulting agreement with Danforth Advisors. His extensive background includes advisory roles at CBIZ and serving as CFO for various life sciences firms, making him well-suited to guide Tenax’s financial strategy.